Pharma Business - June 16, 2016
Medivir investigates possible corporate split
Medivir has announced that the Board of Directors has tasked the company management with reviewing the possibility of dividing the company’s operations into two independent companies and achieving a separate listing for the commercial pharmaceutical portfolio. The Board believes that a division of Medivir’s operations into a dedicated research and development company and a commercial […]
Clinical Trials - January 29, 2016
Medivir initiates phase IIa study
Medivir AB has enrolment of the first patient into a randomized double-blind phase IIa clinical study of the in-house developed cathepsin K inhibitor MIV-711 in patients with moderate knee osteoarthritis (OA). The phase IIa study will enrol 240 patients into 3 arms, each with approximately 80 patients, and compare MIV-711 dosed at 100mg or 200 mg […]
Clinical Trials - January 5, 2016
Medivir’s partner terminates clinical study
Medivir AB announces that the development of AL-704 (also known as JNJ-54257099) has been terminated following completion of phase I clinical studies conducted by Alios Biopharma Inc., one of the Janssen Pharmaceutical Companies. These studies demonstrated that AL-704 was safe, well tolerated and had acceptable pharmacokinetic properties. However its clinical antiviral activity in persons infected […]
Pharma Business - November 17, 2015
Medivir terminates cancer project
Medivir AB will terminate its ADAM8 inhibitor project for pancreatic cancer. The closure of the project follows a semi-annual review of the company’s R&D project portfolio, which deprioritized the project based on data generated during the last six months. As a consequence the license agreement with Cancer Research Technology (CRT) for ADAM8 inhibitors and the […]
Clinical Trials - October 10, 2014
Promising results from Medivir’s pain study
Medivir announces that promising data from its cathepsin S inhibitor drug development program for neuropathic pain will be presented at The 15th World Congress on Pain. The data to be presented support the development of a potent oral cathepsin S inhibitor such as MIV-247 as a new treatment for neuropathic pain. MIV-247 is a potent and […]
In a new job - August 11, 2014
Medivir gets new CEO
The company’s Board of Directors has appointed Niklas Prager as new President and CEO of Medivir AB effective 1 September 2014. Prager will succeed Maris Hartmanis who now leaves the position of President and CEO of Medivir. Niklas Prager holds a Degree of Master of Science in Business Administration and Economics from the Stockholm School […]
